CA2109579A1 - Vecteurs d'expression eucaryotiques avec regulation de la maturation de l'arn - Google Patents

Vecteurs d'expression eucaryotiques avec regulation de la maturation de l'arn

Info

Publication number
CA2109579A1
CA2109579A1 CA002109579A CA2109579A CA2109579A1 CA 2109579 A1 CA2109579 A1 CA 2109579A1 CA 002109579 A CA002109579 A CA 002109579A CA 2109579 A CA2109579 A CA 2109579A CA 2109579 A1 CA2109579 A1 CA 2109579A1
Authority
CA
Canada
Prior art keywords
cells
vector
foreign gene
gene
vector according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002109579A
Other languages
English (en)
Inventor
Julianna Lisziewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2109579A1 publication Critical patent/CA2109579A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002109579A 1991-05-29 1992-05-21 Vecteurs d'expression eucaryotiques avec regulation de la maturation de l'arn Abandoned CA2109579A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70705591A 1991-05-29 1991-05-29
US07/707,055 1991-05-29

Publications (1)

Publication Number Publication Date
CA2109579A1 true CA2109579A1 (fr) 1992-12-10

Family

ID=24840175

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002109579A Abandoned CA2109579A1 (fr) 1991-05-29 1992-05-21 Vecteurs d'expression eucaryotiques avec regulation de la maturation de l'arn

Country Status (5)

Country Link
EP (1) EP0588914A1 (fr)
JP (1) JPH06510181A (fr)
AU (1) AU2007392A (fr)
CA (1) CA2109579A1 (fr)
WO (1) WO1992021750A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732978B1 (fr) * 1995-04-14 1997-05-30 Inst Nat Sante Rech Med Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
DE19617851A1 (de) * 1996-05-03 1997-11-13 Hoechst Ag Nukleinsäurekonstrukte mit Genen kodierend für Transportsignale
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
GB9621679D0 (en) * 1996-10-17 1996-12-11 Oxford Biomedica Ltd Improved retroviral vectors
NZ334860A (en) 1996-10-17 2001-02-23 Oxford Biomedica Ltd Retroviral vectors with one or more auxiliary genes vpr, vif, tat and nef to be absent; with evidence that if all auxiliary genes absent the transduction efficiency is greatest
US7198784B2 (en) 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
JP2001517433A (ja) 1997-09-24 2001-10-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 非霊長類レンチウイルスベクターおよびパッケージングシステム
ATE528405T1 (de) 1997-12-22 2011-10-15 Oxford Biomedica Ltd Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren
US6979568B1 (en) * 1999-06-22 2005-12-27 Dnavec Research, Inc. Vector for the expression of two foreign genes

Also Published As

Publication number Publication date
EP0588914A1 (fr) 1994-03-30
WO1992021750A1 (fr) 1992-12-10
AU2007392A (en) 1993-01-08
JPH06510181A (ja) 1994-11-17

Similar Documents

Publication Publication Date Title
Miyoshi et al. Development of a self-inactivating lentivirus vector
Logan et al. Factors influencing the titer and infectivity of lentiviral vectors
Naviaux et al. The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses
Dull et al. A third-generation lentivirus vector with a conditional packaging system
Sutton et al. Human immunodeficiency virus type 1 vectors efficiently transduce human hematopoietic stem cells
Sakoda et al. A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes
EP0832980B1 (fr) Thérapie recombinante des infections et désordres hyperprolifératifs
CA2114416C (fr) Vecteurs retroviraux contenant des sites de fixation internes pour les ribosomes
Kim et al. Construction of retroviral vectors with improved safety, gene expression, and versatility
Berkowitz et al. Construction and molecular analysis of gene transfer systems derived from bovine immunodeficiency virus
JP2001502903A (ja) レンチウィルスベクター
JPH11512615A (ja) 非分裂細胞への核酸運搬のためのベクターおよび使用方法
CA2109579A1 (fr) Vecteurs d'expression eucaryotiques avec regulation de la maturation de l'arn
Jäger et al. Endothelial cell-specific transcriptional targeting from a hybrid long terminal repeat retrovirus vector containing human prepro-endothelin-1 promoter sequences
CA2237000A1 (fr) Lignees cellulaires stables d'encapsidation produisant un retrovirus pseudotype
Bunnell et al. Retrovirus-mediated gene transfer
US20060024279A1 (en) Retroviral vectors
Matukonis et al. Development of second-and third-generation bovine immunodeficiency virus-based gene transfer systems
Saulnier et al. Lentivirus‐mediated gene transfer of gp91phox corrects chronic granulomatous disease (CGD) phenotype in human X‐CGD cells
Mautino et al. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense
US6620595B2 (en) Retroviral vectors comprising an enhanced 3′ transcription termination structure
Kim et al. Production of high-titer retroviral vectors and detection of replication-competent retroviruses
JP2001502884A (ja) アンチセンスｒｎａ発現によるｈｉｖ―１複製の阻害
EP0977881B1 (fr) Expression d'une proteine d'enveloppe modifiee de virus spumeux
JP2003500050A (ja) 改善されたベクターの選択方法

Legal Events

Date Code Title Description
FZDE Dead